Back

ImmunityBio shares jump 12% to $8.83 as Anktiva market outlook expands

Verifying
  • ImmunityBio shares closed higher as investors assessed Anktiva’s commercial expansion.
  • $8.83 was ImmunityBio’s September 29, 2026 closing price after a gain exceeding 12%.
  • The Phase 1b bladder-cancer study has not started enrolling patients, with records last revised September 21, 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.